SCHEMBL24118252

SCHEMBL24118252

C=C(CCNC(=O)c1ccc(C)c(C)n1)[C@H](C)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 5/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MAPT P10636 3/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ POLB P06746 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ GBA1 P04062 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ P4HTM Q9NXG6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24118074 0.90 SMN1; SMN2 (0.41) GCGRSMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL24118337 0.84 SMN1; SMN2 (0.41) GCGRSMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL24117960 0.82 HIF1A (0.47) SMN1; SMN2KMT2AMEN1CYP1A2CYP2C9
SCHEMBL24118187 0.82 IDO1 (0.56) GCGRSMN1; SMN2KMT2AMEN1MAPT
SCHEMBL24118233 0.82 IDO1 (0.56) GCGRSMN1; SMN2KMT2AMEN1MAPT
SCHEMBL24118292 0.80 RAB9A (0.46) SMN1; SMN2KMT2AMEN1CYP1A2CYP2C9
SCHEMBL24118244 0.80 ALDH1A1 (0.51) SMN1; SMN2KMT2AMEN1L3MBTL1MAPT
SCHEMBL24118612 0.78 L3MBTL1 (0.40) SMN1; SMN2KMT2AMEN1CYP1A2CYP2C9
SCHEMBL24118254 0.78 FPR2 (0.48) KMT2AMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL24118272 0.78 MEN1 (0.44) SMN1; SMN2KMT2AMEN1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 GCGR 3754/4885SMN1; SMN2 2675/4885KMT2A 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback